Welch Allyn adds Nonin to partner trio for next-gen vital sign device

Welch Allyn has partnered with Nonin Medical for its blood oxygen level measurement technology, PureSAT SpO2. It plans to use this technology, alongside others in-licensed from Masimo ($MASI) and Covidien, which is now part of Medtronic ($MDT), to create a next-generation vital sign device that's intended to enable customized vital sign capture, interval monitoring and wireless transfer of patient data to an electronic medical record.

"Blood oxygen level is an important vital sign that provides feedback on a patient's overall health status," Shawn St. Pierre, senior global category manager of vital signs at Welch Allyn, said in a statement. "With technologies constantly evolving, offering solutions from Masimo, Nonin Medical, and Covidien provides our customers with access to more innovations."

Nonin's PureSAT uses pulse-by-pulse filtering to offer more precise oximetry measurements even with motion, low perfusion or other difficult patient conditions. It prefilters the pulse signals and applies algorithms to them to separate pulse signals from artifacts or interference.

Welch Allyn has been aggressively wheeling and dealing of late--making a series of partnerships, acquisitions and investments to bring in complementary technologies.

Most recently, it bought remote diabetic eye exam maker Hubble Telemedical and the telehealth assets of HealthInterlink. It also participated in a financing for contact-free monitoring company EarlySense as well as partnered with Gentag on wearables and LKC for a diabetic retinopathy device.

- here is the release

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.